A model‐based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP‐7000, a new, long‐acting, sustained‐released formulation of risperidone

PsN-Toolkit—A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM

Lindbom, L., Pihlgren, P., & Jonsson, E. N. (2005) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2005.04.005 · Cited by 1,137 · see citing works

Xpose—an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

Jonsson, E. N., & Karlsson, M. O. (1998) · Computer Methods and Programs in Biomedicine · doi:10.1016/s0169-2607(98)00067-4 · Cited by 1,003 · see citing works

Compliance With Medication Regimens for Mental and Physical Disorders

Cramer, J. A., & Rosenheck, R. (1998) · Psychiatric Services · doi:10.1176/ps.49.2.196 · Cited by 725 · see citing works

Predictors of Noncompliance in Patients With Schizophrenia

Perkins, D. O. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1206 · Cited by 546 · see citing works

Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies

Savić, R. M., Jonker, D. M., Kerbusch, T., & Karlsson, M. O. (2007) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-007-9066-0 · Cited by 503 · see citing works

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

Hicks, J. K., Swen, J. J., Thorn, C. F., Sangkuhl, K., Kharasch, E. D., Ellingrod, V. L., Skaar, T. C., Müller, D., Gaedigk, A., & Stingl, J. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.2 · Cited by 454 · see citing works

Guidelines for depot antipsychotic treatment in schizophrenia

Kane, J. M., Aguglia, E., Altamura, A. C., Gutiérrez, J. L., Brunello, N., Fleischhacker, W. W., Gaebel, W., Gerlach, J., Guelfi, J.-D., Kissling, W., et al. (1998) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(97)00045-x · Cited by 331 · see citing works

Factors influencing relapse in the long-term course of schizophrenia

Ayuso-Gutiérrez, J. L., & Vega, J. M. D. R. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(97)00131-x · Cited by 203 · see citing works

Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States

Sun, S. X., Liu, G. G., Christensen, D. B., & Fu, A. Z. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x226050 · Cited by 196 · see citing works

Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia: A Novel Once-Monthly, Long-Acting Formulation of an Atypical Antipsychotic

Samtani, M. N., Vermeulen, A., & Stuyckens, K. (2009) · Clinical Pharmacokinetics · doi:10.2165/11316870-000000000-00000 · Cited by 170 · see citing works

Long Term Depot Antipsychotics

Barnes, T. R. E., & Curson, D. A. (1994) · Drug Safety · doi:10.2165/00002018-199410060-00005 · Cited by 130 · see citing works

Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta™) in patients with schizophrenia

Gefvert, O., Eriksson, B., Persson, P., Helldin, L., Björner, A., Mannaert, E., Remmerie, B., Eerdekens, M., & Nyberg, S. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004924 · Cited by 119 · see citing works

Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study

Feng, Y., Pollock, B. G., Coley, K. C., Marder, S. R., Miller, D. D., Kirshner, M. A., Aravagiri, M., Schneider, L. S. S., & Bies, R. R. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03276.x · Cited by 86 · see citing works

Antipsychotic efficacy: Relationship to optimal D2-receptor occupancy

Pani, L., Pira, L., & Marchese, G. (2007) · European Psychiatry · doi:10.1016/j.eurpsy.2007.02.005 · Cited by 78 · see citing works

The Bioavailability and Pharmacokinetics of Oral and Depot Intramuscular Haloperidol in Schizophrenic Patients

Nayak, R. K., Doose, D. R., & Nair, N. P. V. (1987) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1987.tb02175.x · Cited by 55 · see citing works

Quality of life in schizophrenia: a grounded theory approach.

Gee, L., Pearce, E., & Jackson, M. C. (2003) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-1-31 · Cited by 54 · see citing works

Adherence and Long-Acting Injectable Antipsychotics in Schizophrenia: An Update

Mohr, P., & Volavka, J. (2012) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.5350/dajpn20122504001 · Cited by 5 · see citing works

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview

Correll, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R. (2021) · CNS Drugs · doi:10.1007/s40263-020-00779-5 · Cited by 205 · see citing works

Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities

Krogmann, A., Peters, L., von Hardenberg, L., Bödeker, K., Nöhles, V. B., & Correll, C. U. (2019) · CNS Spectrums · doi:10.1017/s109285291900124x · Cited by 116 · see citing works

A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone

Schoretsanitis, G., Spina, E., Hiemke, C., & de León, J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1345623 · Cited by 94 · see citing works

Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia

Nasser, A. F., Henderson, D. C., D, M. F. M., Fudala, P. J., Twumasi‐Ankrah, P., Kouassi, A., & Heidbreder, C. A. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000479 · Cited by 53 · see citing works

Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs.

Schoretsanitis, G., Baumann, P., Conca, A., Dietmaier, O., Giupponi, G., Gründer, G., Hahn, M., Hart, X., Havemann-Reinecke, U., Hefner, G., et al. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000830 · Cited by 28 · see citing works

Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder

Laffont, C. M., Goméni, R., Heidbreder, C. A., Jones, J. P., & Nasser, A. F. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.665 · Cited by 50 · see citing works

New Antipsychotic Medications in the Last Decade

Pahwa, M., Sleem, A., Elsayed, O. H., Good, M. E., & El‐Mallakh, R. S. (2021) · Current Psychiatry Reports · doi:10.1007/s11920-021-01298-w · Cited by 49 · see citing works

A Population Pharmacokinetic and Pharmacodynamic Modelling Approach to Support the Clinical Development of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Dependence

Nasser, A. F., Heidbreder, C. A., Goméni, R., Fudala, P. J., Zheng, B., & Greenwald, M. K. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0155-0 · Cited by 44 · see citing works

Population Pharmacokinetics and Prediction of Dopamine D2 Receptor Occupancy After Multiple Doses of RBP‐7000, a New Sustained‐Release Formulation of Risperidone, in Schizophrenia Patients on Stable Oral Risperidone Treatment

Laffont, C. M., Gomeni, R., Zheng, B., Heidbreder, C., Fudala, P. J., & Nasser, A. F. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0132-7 · Cited by 35 · see citing works

Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches

Højlund, M., & Correll, C. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2228686 · Cited by 38 · see citing works

Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications

Citrome, L. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1371014 · Cited by 34 · see citing works

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics

Toja-Camba, F. J., Gesto-Antelo, N., Maroñas, O., Arrieta, E. E., Zarra‐Ferro, I., González‐Barcia, M., Bandín‐Vilar, E., Sanjuan, V. M., Facal, F., Arrojo, M., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13070935 · Cited by 29 · see citing works

Population pharmacokinetic modeling and simulation to guide dose selection for RBP‐7000, a new sustained‐release formulation of risperidone

Laffont, C. M., Gomeni, R., Zheng, B., Heidbreder, C., Fudala, P. J., & Nasser, A. F. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.366 · Cited by 26 · see citing works

Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1)

Llaudó, J., Anta, L., Ayani, I., Martínez, J., Schronen, J., Ma, M., Ivanov, M. V., & Gutierro, I. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000139 · Cited by 26 · see citing works

Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia

Dammerman, R. S., Kim, S., Adera, M., & Schwarz, A. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.428 · Cited by 26 · see citing works

Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study

Isitt, J. J., Nadipelli, V. R., Kouassi, A., D, M. F. M., & Heidbreder, C. A. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.03.020 · Cited by 24 · see citing works

Exposure‐response analysis after subcutaneous administration of RBP‐7000, a once‐a‐month long‐acting Atrigel formulation of risperidone

Ivaturi, V. D., Gopalakrishnan, M., Gobburu, J. V. S., Zhang, W., Liu, Y., Heidbreder, C. A., & Laffont, C. M. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13246 · Cited by 24 · see citing works

A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia

Anta, L., Llaudó, J., Ayani, I., Martínez, J., Litman, R. E., & Gutierro, I. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000203 · Cited by 23 · see citing works

Emerging pharmacological therapies in schizophrenia: what’s new, what’s different, what’s next?

Citrome, L. (2016) · CNS Spectrums · doi:10.1017/s1092852916000729 · Cited by 22 · see citing works

Population Pharmacokinetic Modeling and Simulation of TV‐46000: A Long‐Acting Injectable Formulation of Risperidone

Perlstein, I., Wagner, A. M., Goméni, R., Lamson, M. J., Harary, E., Spiegelstein, O., Kalmanczhelyi, A., Tiver, R., Loupe, P. S., Levi, M., et al. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1078 · Cited by 18 · see citing works

Model‐Based Approach for Optimizing Study Design and Clinical Drug Performances of Extended‐Release Formulations of Methylphenidate for the Treatment of ADHD

Goméni, R., Bressolle, F., Spencer, T., Faraone, S. V., Fang, L., & Babiskin, A. H. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.684 · Cited by 18 · see citing works

Newer Formulations of Risperidone: Role in the Management of Psychotic Disorders

Clark, I., & Taylor, D. M. (2020) · CNS Drugs · doi:10.1007/s40263-020-00735-3 · Cited by 17 · see citing works

Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations

Schoretsanitis, G., Meyer, J. M., Conca, A., & Hiemke, C. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2220962 · Cited by 15 · see citing works

Modeling Complex Pharmacokinetics of Long‐Acting Injectable Products Using Convolution‐Based Models With Nonparametric Input Functions

Goméni, R., & Bressolle, F. (2021) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1842 · Cited by 13 · see citing works

Risperidone ISM ® : review and update of its usefulness in all phases of schizophrenia

Messer, T., Bernardo, M., Anta, L., & Martínez, J. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241280046 · Cited by 10 · see citing works

PerserisTM: A New and Long-Acting, Atypical Antipsychotic Drug-Delivery System.

Karas, A., Burdge, G., & Rey, J. A. (2019) · Europe PMC (PubMed Central) · Cited by 9 · see citing works

Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations

Tchobaniouk, L. V., McAllister, E., Bishop, D. L., Carpentier, R., Heins, K. R., Haight, R. J., & Bishop, J. R. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s192418 · Cited by 7 · see citing works

Exposure‐Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM

Lindauer, A., Snoeck, E., Laveille, C., Ayani, I., D., L. O., Almendros, M., Martínez, J., Anta, L., & Gutierro, I. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6152 · Cited by 5 · see citing works

Use of predictive models in CNS diseases

Goméni, R. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.10.004 · Cited by 5 · see citing works

Supercritical fluid fabrication of components for a sustained-release injectable risperidone dose form

Bagratashvili, V. N., Богородский, С. Э., Egorov, A. M., Кротова, Л. И., Popov, V. K., & Sevast’yanov, V. I. (2016) · Russian Journal of Physical Chemistry B · doi:10.1134/s1990793116070022 · Cited by 5 · see citing works

Comparison of dopamine D2 receptor occupancy profiles between risperidone ISM versus oral risperidone and monthly paliperidone palmitate based on population pharmacokinetic modelling and simulations

Snoeck, E., Luyckx, N., Lindauer, A., D., L. O., Anta, L., Martínez, J., & Gutierro, I. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2594496 · Cited by 4 · see citing works

Population Pharmacokinetics of Risperidone and Paliperidone in Schizophrenia: A Systematic Review

Carrascosa-Arteaga, A., Nalda‐Molina, R., Más‐Serrano, P., & Ramón-López, A. (2025) · Pharmaceuticals · doi:10.3390/ph18050698 · Cited by 4 · see citing works

Modeling of prolactin response following dopamine D2 receptor antagonists in rats: can it be translated to clinical dosing?

Taneja, A., Vermeulen, A., Huntjens, D., Danhof, M., de Lange, E., & Proost, J. (2017) · Pharmacology Research & Perspectives · doi:10.1002/prp2.364 · Cited by 2 · see citing works

The place of risperidone in situ microparticles (ISM®) among long-acting injectable antipsychotics in schizophrenia treatment

de Filippis, R., D’Onofrio, E., Liparota, G., Scaramuzzino, A., Aguglia, A., Amerio, A., Serafini, G., & Fazio, P. D. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2551636 · Cited by 2 · see citing works

Prescribing LAIs: from completing the first injection to going steady

Cutler, A. J., & Grady, M. M. (2025) · CNS Spectrums · doi:10.1017/s1092852925100588 · Cited by 1 · see citing works

Risperidone Oral and Long-Acting Injectable; Paliperidone Oral and Long-Acting Injectable

Meyer, J. M., & Stahl, S. M. (2021) · Cambridge University Press eBooks · doi:10.1017/9781009002103.017

Advancing Long-Acting Formulations for Treating Chronic Diseases

Nayan, M. U., Sultana, A., Le, N. T. H., Poluektuva, L. Y., Edagwa, B., & Gendelman, H. E. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_37

The Reservoir Effect: Implications for Safety and Regulation of Long-acting Injectables in Psychiatric Care

Sawale, J. A., Kaur, P., Arora, N., Rangra, N. K., Kaur, S., Chawla, R. L., Chauhan, B., & Singh, A. (2026) · Recent Advances in Inflammation & Allergy Drug Discovery · doi:10.2174/0127722708436018260101153044

Population pharmacokinetic modeling and simulation to guide dose selection for RBP‐7000, a new sustained‐release formulation of risperidone

Laffont, C. M., Gomeni, R., Zheng, B., Heidbreder, C., Fudala, P. J., & Nasser, A. F. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.366 · Cited by 26 · see citing works

Population Pharmacokinetics and Prediction of Dopamine D2 Receptor Occupancy After Multiple Doses of RBP‐7000, a New Sustained‐Release Formulation of Risperidone, in Schizophrenia Patients on Stable Oral Risperidone Treatment

Laffont, C. M., Gomeni, R., Zheng, B., Heidbreder, C., Fudala, P. J., & Nasser, A. F. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0132-7 · Cited by 35 · see citing works

Exposure‐response analysis after subcutaneous administration of RBP‐7000, a once‐a‐month long‐acting Atrigel formulation of risperidone

Ivaturi, V. D., Gopalakrishnan, M., Gobburu, J. V. S., Zhang, W., Liu, Y., Heidbreder, C. A., & Laffont, C. M. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13246 · Cited by 24 · see citing works

Development of a population pharmacokinetic model for the novel long‐acting injectable antipsychotic risperidone ISM®

Laveille, C., Snoeck, E., D., L. O., Martínez, J., Llaudó, J., Anta, L., & Gutierro, I. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16115 · Cited by 8 · see citing works

Population pharmacokinetic-pharmacodynamic (PopPK/PD) modeling of risperidone and its active metabolite in Chinese schizophrenia patients

Ji, S., Shang, D., Wu, K., Li, A., Li, X., Deng, C., Li, L., Zhou, T., Wang, C., & Lu, W. (2016) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp202498 · Cited by 3 · see citing works